Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth R Plimack

Showing results (171-180 of 209) with videos related to

Pageof 21
Sort By:
European Urology|August 5, 2015
Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder CancerElizabeth R Plimack, Roland L Dunbrack, Timothy A Brennan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 10, 2010
NCCN clinical practice guidelines in oncology: prostate cancerJames Mohler, Robert R Bahnson, Barry Boston, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2016
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell CarcinomaToni K Choueiri, Mayer N Fishman, Bernard Escudier, et al.
The New England Journal of Medicine|September 26, 2015
Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaRobert J Motzer, Bernard Escudier, David F McDermott, et al.
Cancer Discovery|February 24, 2025
Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell CarcinomaMiya B Hugaboom, Lena V Wirth, Kelly Street, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 14, 2013
Penile cancer: Clinical Practice Guidelines in OncologyPeter E Clark, Philippe E Spiess, Neeraj Agarwal, et al.
Journal for Immunotherapy of Cancer|July 15, 2020
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trialRobert J Motzer, Bernard Escudier, David F McDermott, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 10, 2017
Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in OncologyRobert J Motzer, Eric Jonasch, Neeraj Agarwal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2023
A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor TherapyH Josh Jang, Galen Hostetter, Alexander W Macfarlane, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 16, 2013
Bladder cancerPeter E Clark, Neeraj Agarwal, Matthew C Biagioli, et al.
Pageof 21

Showing results (171-180 of 209) with videos related to

Sort By:
Pageof 21
European Urology|August 5, 2015
Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder CancerElizabeth R Plimack, Roland L Dunbrack, Timothy A Brennan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 10, 2010
NCCN clinical practice guidelines in oncology: prostate cancerJames Mohler, Robert R Bahnson, Barry Boston, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2016
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell CarcinomaToni K Choueiri, Mayer N Fishman, Bernard Escudier, et al.
The New England Journal of Medicine|September 26, 2015
Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaRobert J Motzer, Bernard Escudier, David F McDermott, et al.
Cancer Discovery|February 24, 2025
Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell CarcinomaMiya B Hugaboom, Lena V Wirth, Kelly Street, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 14, 2013
Penile cancer: Clinical Practice Guidelines in OncologyPeter E Clark, Philippe E Spiess, Neeraj Agarwal, et al.
Journal for Immunotherapy of Cancer|July 15, 2020
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trialRobert J Motzer, Bernard Escudier, David F McDermott, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 10, 2017
Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in OncologyRobert J Motzer, Eric Jonasch, Neeraj Agarwal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2023
A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor TherapyH Josh Jang, Galen Hostetter, Alexander W Macfarlane, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 16, 2013
Bladder cancerPeter E Clark, Neeraj Agarwal, Matthew C Biagioli, et al.
Pageof 21